Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders
US6346517B1 · kind B1 · utility
8Cited by
0References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 10, 2000 |
| Grant date | Feb 12, 2002 |
| Priority date | — |
| Expiry date | Mar 10, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention is directed to a combination therapy comprising the administration of a low molecular weight heparin such as tinzaparin and a platelet GPIIb/IIIa antagonist such as roxifiban for treating, preventing and reducing the risk of thromboembolic disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.